{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:50Z","timestamp":1784196470090,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:49:42Z","timestamp":1776815382000},"page":"657-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Romosozumab Treatment After Parathyroidectomy for Primary Hyperparathyroidism-Complicated Osteoporosis: A Two-Case Report"],"prefix":"10.1016","volume":"13","author":[{"given":"Saya","family":"Takebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-7704","authenticated-orcid":false,"given":"Yasufumi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.aed.2026.04.008_bib1","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad201","article-title":"Stable incidence and increasing prevalence of primary hyperparathyroidism in a population-based study in Scotland","volume":"108","author":"Soto-Pedre","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aed.2026.04.008_bib2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2009-2384","article-title":"Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis","volume":"95","author":"Sankaran","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aed.2026.04.008_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10482","article-title":"The risk of fractures in primary hyperparathyroidism: a meta-analysis","volume":"5","author":"Narayanan","year":"2021","journal-title":"JBMR Plus"},{"issue":"1","key":"10.1016\/j.aed.2026.04.008_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1 Pt A","key":"10.1016\/j.aed.2026.04.008_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.amjsurg.2022.04.031","article-title":"Parathyroidectomy in the elderly is beneficial and safe with similar improvements in postoperative bone mineral density","volume":"224","author":"Hangge","year":"2022","journal-title":"Am J Surg"},{"issue":"10","key":"10.1016\/j.aed.2026.04.008_bib6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.aed.2026.04.008_bib7","first-page":"71","article-title":"New aspects of biologically active substances (5) update on osteoporosis: role of Romosozumab","volume":"94","author":"Tominaga","year":"2024","journal-title":"J Tokyo Womens Med Univ"},{"issue":"15","key":"10.1016\/j.aed.2026.04.008_bib8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.aed.2026.04.008_bib9","doi-asserted-by":"crossref","first-page":"11639","DOI":"10.3390\/ijms252111639","article-title":"Bone disease in primary hyperparathyroidism-changes occurring in bone metabolism and new potential treatment strategies","volume":"25","author":"Iwanowska","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.aed.2026.04.008_bib10","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aed.2026.04.008_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1169249","article-title":"Vitamin D deficiency and the presentation of primary hyperparathyroidism: a mini review","volume":"2023","author":"Yedla","year":"2023","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.aed.2026.04.008_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117701","article-title":"Bone mineral density response to romosozumab in post-menopausal women: a prospective observational real-world study","volume":"202","author":"Gielen","year":"2026","journal-title":"Bone"},{"key":"10.1016\/j.aed.2026.04.008_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clnesp.2022.02.002","article-title":"Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis","volume":"48","author":"Kobayakawa","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"2","key":"10.1016\/j.aed.2026.04.008_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00223-023-01087-y","article-title":"Nonresponder considerations for romosozumab treatment","volume":"113","author":"Tominaga","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1016\/j.aed.2026.04.008_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aed.2026.04.008_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-21-0322","article-title":"Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study","volume":"185","author":"Ryh\u00e4nen","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.aed.2026.04.008_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.surg.2019.04.059","article-title":"Skeletal effects of combined medical and surgical management of primary hyperparathyroidism","volume":"167","author":"Orr","year":"2020","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.aed.2026.04.008_bib18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00774-021-01279-2","article-title":"Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism","volume":"40","author":"Choe","year":"2022","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"10.1016\/j.aed.2026.04.008_bib19","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","article-title":"Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study","volume":"23","author":"Ardawi","year":"2012","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.aed.2026.04.008_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.20945\/2359-3997000000558","article-title":"Medical management of primary hyperparathyroidism","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch Endocrinol Metab"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:41Z","timestamp":1784194601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000834"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.04.008","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romosozumab Treatment After Parathyroidectomy for Primary Hyperparathyroidism-Complicated Osteoporosis: A Two-Case Report","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}